News for BioNTech SE (0A3M.L)

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA candidates. Click for my look at BNTX and CVAC.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

On June 3, 2025, Truist Securities analyst Asthika Goonewardene reiterated a "Buy" rating on BioNTech (BNTX). The analyst also raised the price target for BNTX

Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading following upbeat quarterly results. The company reported fourth-qu...

We recently published a list of These 10 Stocks Blew Past Expectations.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other top-performing stocks on Monday. BioNTech saw its share prices grow by 18.05 percent on Monday to finish at $113.10 apiece following news that it joined forces […]

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market.

Summary BioNTech SE (BNTX) and Bristol Myers Squibb (BMY) have announced a strategic collaboration to co-develop and co-commercialize BioNTech's investigational

Summary Bristol-Myers Squibb Co (BMY) has announced a strategic partnership with BioNTech SE to co-develop and co-commercialize BioNTech's investigational bispe

BioNTech (BNTX) and Bristol Myers Squibb (BMY) enter a global partnership for BNT327. Bristol Myers Squibb will pay $1.5 billion upfront and $2 billion

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and m

The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.

Recent developments in the FDA leadership have stirred investor concerns regarding BioNTech (BNTX) and other vaccine producers. The appointment of Vinay Prasad

Key Highlights: BioNTech shares dropped 5.6% following a significant FDA leadership change. Analysts project an average price target that suggests a pote

On May 6, 2025, Citigroup analyst Geoff Meacham maintained his "Buy" rating on BioNTech (BNTX) while adjusting the price target for the stock. The revised price

On May 6, 2025, Morgan Stanley analyst Terence Flynn announced a revision for BioNTech's (BNTX) stock price target. The target was lowered from $140.00 to $132.

Citi analyst Geoff Meacham has adjusted the price target for BioNTech (BNTX) from $145 to $140, while maintaining a Buy rating on the stock. The recent first-qu

Citi has adjusted its price target for BioNTech (BNTX), lowering it slightly from $145 to $140. Despite this revision, Citi maintains a Buy rating on the shares